To participate in the telephone conference call, dial 1-888-950-8044, pass code BLUD. Replays of the conference call will be available for one week beginning at 12:00 PM on March 12, 2008 by calling 1-866-415-3316. Beginning March 19, 2008, audio of the conference call or a transcript of the audio will be available on the "About Us - Press Releases" page of the Immucor website.
TM Capital Corp. served as financial advisor to Immucor in this transaction, and Lazard Freres & Co. LLC served as financial advisor to BioArray.
Founded in 1982, Immucor manufactures and sells a complete line of reagents and systems used by hospitals, reference laboratories and donor centers to detect and identify certain properties of the cell and serum components of blood prior to transfusion. Immucor markets a complete family of automated instrumentation for all of our market segments.
For more information on Immucor, please visit our website at http://www.immucor.com.
Statements contained in this press release that are not statements of
historical fact are "forward-looking statements" as that term is defined
under federal securities laws, including, without limitation, all
statements concerning Immucor's expectations, beliefs, intentions or
strategies for the future. Factors that could adversely affect the closing
of this transaction or the Company's results after closing include but are
not limited to the following: the possibility that Hart-Scott-Rodino
pre-merger notification clearance may be denied in light of the
recently-announced FTC investigation of past Company acquisitio
|SOURCE Immucor, Inc.|
Copyright©2008 PR Newswire.
All rights reserved